- Home
- ZUO vs SNDX Comparison
ZUO vs SNDX Comparison
Compare ZUO & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZUO
- SNDX
- Stock Information
- Founded
- ZUO 2006
- SNDX 2005
- Country
- ZUO United States
- SNDX United States
- Employees
- ZUO N/A
- SNDX N/A
- Industry
- ZUO EDP Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- ZUO Technology
- SNDX Health Care
- Exchange
- ZUO Nasdaq
- SNDX Nasdaq
- Market Cap
- ZUO 1.5B
- SNDX 1.4B
- IPO Year
- ZUO 2018
- SNDX 2016
- Fundamental
- Price
- ZUO $9.94
- SNDX $13.63
- Analyst Decision
- ZUO Buy
- SNDX Strong Buy
- Analyst Count
- ZUO 7
- SNDX 11
- Target Price
- ZUO $11.43
- SNDX $37.64
- AVG Volume (30 Days)
- ZUO 2.3M
- SNDX 1.9M
- Earning Date
- ZUO 12-09-2024
- SNDX 11-05-2024
- Dividend Yield
- ZUO N/A
- SNDX N/A
- EPS Growth
- ZUO N/A
- SNDX N/A
- EPS
- ZUO N/A
- SNDX N/A
- Revenue
- ZUO $452,763,000.00
- SNDX $16,000,000.00
- Revenue This Year
- ZUO $7.42
- SNDX N/A
- Revenue Next Year
- ZUO $7.04
- SNDX N/A
- P/E Ratio
- ZUO N/A
- SNDX N/A
- Revenue Growth
- ZUO 6.78
- SNDX N/A
- 52 Week Low
- ZUO $7.70
- SNDX $13.26
- 52 Week High
- ZUO $10.85
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- ZUO 58.71
- SNDX 30.64
- Support Level
- ZUO $9.91
- SNDX $13.36
- Resistance Level
- ZUO $9.97
- SNDX $14.18
- Average True Range (ATR)
- ZUO 0.04
- SNDX 0.81
- MACD
- ZUO -0.02
- SNDX -0.18
- Stochastic Oscillator
- ZUO 33.33
- SNDX 11.32
About ZUO Zuora Inc.
Zuora Inc provides cloud-based software on a subscription basis that enables companies in various industries to launch, manage, and transform into a subscription business. The firm offers a Zuora Central platform that acts as an intelligent subscription management hub that automates the subscription order-to-cash process, including quoting, billing, collections, analytics, and revenue recognition. Its products include Zuora Billing, Zuora Revenue, Zuora Payments, Zephr, Zuora Platform, and other software that support and expand upon the core offerings. Geographically, it derives a majority of its revenue from the United States.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.